Summary of Jim Wells and Michelle Arkin(UCSF) Part 1: Introduction to Drug Discovery

Summary of Main Ideas and Concepts

The video features Jim Wells and Michelle Arkin from UCSF discussing the Drug Discovery process, focusing on the screening of compounds and hit identification. The presentation is divided into two parts, with Jim providing a historical overview and methodology, while Michelle elaborates on practical aspects of hit identification.

Key Concepts and Lessons:

• Historical Context of Drug Discovery
  • Drug Discovery has evolved from natural product screening to modern systematic methods.
  • The establishment of the FDA in 1906 was a pivotal moment for drug regulation and safety.
  • Early Drug Discovery relied on natural sources (e.g., aspirin from tree bark) and animal testing.
• Modern Drug Discovery Process
  • The process starts with identifying a disease and determining its molecular target.
  • Key stages include:
    • Target Identification: Understanding the biological basis of the disease.
    • Lead Discovery: Finding compounds that interact with the identified target.
    • Lead Optimization: Enhancing the properties of the identified compounds for efficacy and safety.
    • IND Enabling: Preparing compounds for clinical trials, including safety and efficacy testing.
    • Clinical Trials: Conducting phased trials to assess safety, efficacy, and optimal dosing.
• Types of Drugs
  • Small Molecule Drugs: Typically organic compounds with a molecular weight under 500 Daltons.
  • Protein Therapeutics: Larger molecules often administered via injection.
  • Vaccines: Biological agents that elicit immune responses.
• Hit Identification
  • The initial stage of Drug Discovery involves finding compounds that engage the target effectively.
  • Strategies for hit identification include:
    • Modifying natural substrates to enhance drug-like properties.
    • Utilizing existing compounds to improve upon known liabilities.
    • Designing compounds based on structural knowledge of targets (structure-based design).
    • High Throughput Screening (HTS) as a common method for identifying active compounds.
• High Throughput Screening (HTS)
  • HTS allows for the rapid testing of large libraries of compounds (100,000 to over a million).
  • The process involves miniaturization and automation to efficiently handle numerous assays.
  • Libraries can be derived from natural products, structure-based designs, or diversity selections.
• Assay Development
  • Assays can be biochemical (measuring enzyme activity) or cell-based (testing compounds in live cells).
  • High content imaging and fluorescence assays are popular for analyzing cellular responses to compounds.
• Data Analysis and Selection
  • After screening, compounds are evaluated based on their potency and potential for further development.
  • Metrics like Z-prime values help assess the quality of the assays and select promising candidates for optimization.

Methodology and Instructions

• Drug Discovery Process:
  • Identify the disease and its molecular target.
  • Conduct biochemical and cellular assays to find compounds that interact with the target.
  • Optimize lead compounds based on potency, selectivity, and safety.
  • Prepare for IND submission and conduct clinical trials.
• Hit Identification Techniques:
  • Start with natural substrates or known compounds.
  • Use structure-based design for new compounds.
  • Implement HTS to screen large libraries effectively.
  • Analyze hits through biochemical and cell-based assays.
• HTS Process:
  • Use miniaturization (e.g., 96-well, 384-well plates) to conduct multiple experiments.
  • Automate processes with robotics for high-throughput data collection.
  • Utilize plate readers to analyze results and determine compound efficacy.

Featured Speakers

• Jim Wells, UCSF
• Michelle Arkin, UCSF

Notable Quotes

— 02:09 — « Today, the weather was ok. »

— 03:02 — « Dog treats are the greatest invention ever. »

Category

Educational

Video